"I Always Want to Lead, Not Follow": Kiran Mazumdar Shaw's Journey to the Top of Biosimilars and Her Vision for Biocon's Future

Kiran Mazumdar Shaw: Biotech Leader on Daring to Differentiate

Kiran Mazumdar Shaw, the Executive Chairperson of Biocon, stands as a prominent figure in the global biotechnology landscape, having built a nearly ten-billion-dollar group of companies from the ground up. Often describing herself as an "accidental entrepreneur," her journey reveals a strong combination of ambitious vision, a relentless drive to innovate, and a practical financial approach rooted in middle-class sensibilities. Her core philosophy, "I've always wanted to differentiate; I never wanted to be a me-too. I always want to lead, not follow," has been the guiding principle behind Biocon's ascent.

Join the Whatsapp Channel to Get News updates in english

Her entry into entrepreneurship was serendipitous, stemming from an inability to secure a position in Indian breweries after her training in Australia, simply because she was a woman. This setback led her to an encounter with an Irish entrepreneur seeking an Indian partner for an enzyme business, a venture she embraced, never looking back. While the start may have been unplanned, her subsequent actions demonstrated clear ambition. This was evident when she made the bold move to buy back Biocon from Unilever in the late 1990s, a decision that has since fueled the company's significant growth.

Mazumdar-Shaw's ambition is not just about growth, but about market leadership. Speaking about Biocon's position in the biosimilars market, she articulates a clear goal: "Now, we are in the top five when it comes to biosimilars; I want to be at the top in five years." This drive for preeminence is coupled with a preference for autonomy, as she expresses a reluctance towards strategic investors who might dilute this core aspiration. "I don't want a strategic investor to spoil that aspiration," she states, underscoring her confidence in Biocon's potential and her willingness to pursue growth independently.

This desire to "lead, not follow" is a recurring theme. "I've challenged the status quo," Mazumdar-Shaw explains. "And when I see the sector going a certain way, I want to go the other way. Because that's the way you stand out. That's the way you take that calculated risk, and then you are a leader." This approach, she believes, is key to remaining relevant and at the cutting edge of the industry. Even her personal style, preferring scarves over saris because they "light up the attire and they are not expensive," subtly reflects this ethos of differentiation and practicality.

Despite her appetite for risk, Mazumdar-Shaw’s strategies are deeply informed by her middle-class upbringing, emphasizing calculated risks and diligent mitigation. "You take a calculated risk and make sure that you keep mitigating that risk and making sure that it translates into huge success," she notes. This financial prudence is also evident in her aversion to excessive debt. Her late husband, John Shaw, a former chairman of Madura Coats, played a significant role in reinforcing this financial discipline. She recalls his philosophy: "Biocon is scientifically aggressive, but financially frugal."

The acquisition of Viatris Ltd.'s biosimilars business for $3.3 billion, which involved taking on substantial debt for Biocon Biologics, tested this principle. While her husband initially hesitated, he ultimately supported the move, cautioning her to "make sure that you don't bet the bank on it... Make sure that you drive this business well, so that it can service the debt." This advice, combined with her inherent wariness of high debt, led Biocon to subsequently lower its debt by raising equity.

While some investors have pointed to Biocon's historically modest Return on Equity (ROE), this is often attributed to the capital-intensive nature and long gestation periods typical of the biosimilars industry. However, with a pipeline of new drug launches, improved returns are anticipated.

Mazumdar-Shaw's entrepreneurial spirit extends beyond Biocon. She actively invests in various startups, particularly in the Bangalore area, driven by her passion for biology and its technological applications. "Biology is the new frontier, thanks to technology; technology-enabled biology is the most exciting area to be a startup entrepreneur," she believes. Her investments include companies like BugWorks, developing antimicrobial-resistant drugs, C6 Energy, focused on biofuels from seaweed, and Immuneel, a cell and gene therapy company she co-founded.

Her focus is consistently on harnessing knowledge for enterprise, a hallmark of her middle-class value for learning. Looking ahead, while confident in the professional management of Biocon and its group companies like Syngene, Mazumdar-Shaw is also considering succession at the board level, potentially grooming capable family members for future leadership roles. Her journey shows a powerful blend of visionary leadership and grounded pragmatism.